Amanda Spence
Family · New Britain, CTNPI 1437624087
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 416 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 42 manufacturers reported payments, led by AbbVie at 25.9% of the total. 2025 is the largest year on record at $3,057, more than ten times the $14 reported in 2021. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 416 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$475
- Lilly USA, LLC$436
- GSK$415
- Neurocrine Biosciences, Inc.$391
- Pfizer$389
- plus $4K from 36 others
What the payments were for
- Food & beverage$7,769100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,788 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $33,349 |
| JardianceEmpagliflozin | 13 | $16,028 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $15,926 |
| EliquisApixaban | 28 | $9,865 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $805 |
| Atorvastatin Calcium | 108 | $725 |
| Rosuvastatin Calcium | 24 | $589 |
| Methylprednisolone | 54 | $475 |
| Valsartan | 20 | $374 |
| Amlodipine Besylate | 55 | $368 |
| Ezetimibe | 15 | $313 |
| Olmesartan Medoxomil | 20 | $282 |
| Lisinopril | 50 | $275 |
| Gabapentin | 20 | $267 |
| Doxycycline Hyclate | 44 | $260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $475 | $33,34935 claims |
| Boehringer IngelheimJardiance | $184 | $16,02813 claims |
| PfizerEliquis, Paxlovid | $389 | $9,86553 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $129 | $21441 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in New Britain
- Kathryn TierneyNew Britain$140K
- Elisha ChristiansonWaterbury$371K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
- Nicole SandilandsBridgeport$30K
- Ralph HirschfeldPutnam$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.